Inclusion Criteria:  Age ≥ 18 years Signed Informed Consent Form ECOG performance status of 0 or 1 Histologically confirmed intermediate risk non muscle-invasive urothelial carcinoma of the bladder (pTa low grade) Patients Representative fresh tumor specimen for PDO generation and drug screen  Exclusion Criteria:  Known previous high grade and/or high risk non muscle-invasive bladder cancer Previous Intravesical biological/immuno (BCG) therapy Pregnancy or nursing Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol Severe infection within 4 weeks prior to cycle 1, day 1 Contraindication for frequent catheterization Voiding dysfunction